1. Home
  2. Vaccines, Blood & Biologics
  3. Vaccines
  4. Influenza Vaccine Composition for the 2026-2027 U.S. Influenza Season
  1. Vaccines

Influenza Vaccine Composition for the 2026-2027 U.S. Influenza Season

FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met on March 12, 2026, to discuss and make recommendations on the selection of influenza viruses for the composition of influenza vaccines for the 2026-2027 U.S. influenza season. During this meeting, the advisory committee evaluated and analyzed global and U.S. surveillance data related to the epidemiology and antigenic characteristics of recent influenza virus isolates, serological responses to 2025-2026 influenza vaccines, and the availability of candidate influenza virus strains and reagents.

Seasonal influenza vaccines include two influenza A viruses (H1N1 and H3N2) and one influenza B virus. Influenza virus strains were selected based on the influenza vaccine production method: egg-based and cell- or recombinant-based.

The committee recommended that the formulation of egg-based influenza vaccines for the 2026-2027 U.S. influenza season contain the following:

  • an A/Missouri/11/2025 (H1N1)pdm09-like virus;
  • an A/Darwin/1454/2025 (H3N2)-like virus; and
  • a B/Tokyo /EIS13-175/2025 (B/Victoria lineage)-like virus.

The committee recommended that the formulation of cell- or recombinant-based influenza vaccines for the 2025-2026 U.S. influenza season contain the following:

  • an A/Missouri/11/2025 (H1N1)pdm09-like virus;
  • an A/Darwin/1415/2025 (H3N2)-like virus; and
  • a B/Pennsylvania/14/2025 (B/Victoria lineage)-like virus.

FDA has informed the manufacturers of FDA-approved seasonal influenza vaccines of these recommendations. FDA anticipates that there will be an adequate and diverse supply of approved seasonal influenza vaccines for the 2026-2027 U.S. influenza season.

Back to Top